AdimrSC-2f

BIOLOGICAL2 trials

Sponsors

Adimmune Corporation

Conditions

COVID-19

Phase 1

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

CompletedNCT04522089

Adimmune CorporationCOVID-19

Start: 2020-08-24End: 2021-05-06Updated: 2022-05-24

Dose-finding Study for AdimrSC-2f Vaccine

CompletedNCT05104489

Adimmune CorporationCOVID-19

Start: 2022-01-03End: 2023-07-26Updated: 2023-07-28